On December 7, at the Guangzhou 2025 Innovation Drug High-Quality Development Conference, the first edition of the "Commercial Health Insurance Innovation Drug List" (referred to as the "Innovation Drug List") was released alongside the 2025 National Basic Medical Insurance Drug List, marking a critical step in the construction of China's multi-level healthcare security system.

Covering 19 drugs from 18 pharmaceutical companies, the list will take effect on January 1, 2026. It includes high-value innovative drugs such as million-dollar CAR-T cancer therapies, as well as treatments for rare diseases and Alzheimer's disease, serving as a key institutional bridge between basic medical insurance and differentiated commercial health insurance coverage.

The National Healthcare Security Administration emphasized that the Innovation Drug List focuses on drugs with "high innovation, significant clinical value, and substantial patient benefits beyond basic medical insurance coverage," recommending their adoption by commercial health insurance and mutual medical aid systems. Industry experts describe its core feature as "dual integration"—building on the eight-year foundation of the national medical insurance list while aligning with the product characteristics and risk management needs of commercial health insurance, providing a policy framework for coordinated development between public and private insurance.

**Strict Selection: A 15.7% Approval Rate Reflects Value-Based Choices** The creation of the first Innovation Drug List involved a rigorous selection process. Out of 121 drugs initially submitted for review, only 24 advanced to price negotiations, with 19 ultimately making the final cut—a 15.7% approval rate. This cautious approach reflects a multi-faceted evaluation of clinical value, innovation, and commercial insurance feasibility, balancing patient needs with insurance sustainability.

Cancer treatments dominate the list, accounting for 14 of the 19 drugs. Five CAR-T cell therapies, priced between RMB 999,000 and RMB 1.2 million per dose, were fully included—a major highlight. These "anti-cancer breakthroughs" have previously been excluded from national medical insurance due to high costs but remain central to commercial insurance products like "Huiminbao." Heyuan Bio CEO Lu Lulu noted that their CAR-T therapy, Naquio Injection, has already been included in over a dozen Huiminbao programs since its 2023 launch, and nationwide adoption under the Innovation Drug List will significantly improve accessibility.

Two Alzheimer's drugs—Eisai's Lecanemab and Eli Lilly's Donanemab—were also included, with annual treatment costs around RMB 180,000. Their inclusion will allow partial cost coverage through commercial insurance, easing financial burdens. Both drugs are under preliminary review for the 2025 national medical insurance list, suggesting a potential transition from commercial to basic insurance coverage—a model reflecting "commercial insurance paving the way for public insurance."

Six rare disease drugs made the list, addressing conditions like neuroblastoma and genetic disorders. For example, Dinutuximab Beta, priced at RMB 300,000–500,000 per course for pediatric neuroblastoma, meets urgent clinical needs despite low case numbers. CanSino Biologics CEO Xue Qun highlighted that inclusion accelerates market access and payment solutions for high-cost rare disease treatments.

**Implementation Challenges: From Policy to Patient Access** The list's release is just the beginning. Translating "paper coverage" into real patient benefits requires collaboration among insurers, hospitals, and regulators. Huiminbao, as the most widespread commercial insurance, is expected to be the primary vehicle for adoption.

The National Healthcare Security Administration outlined two key implementation pathways: integrating listed drugs into hospital and pharmacy networks (similar to negotiated医保 drugs) and encouraging insurers to design new products or update coverage based on the list. The policy allows flexibility, as adoption remains voluntary for insurers.

Guangdong Province, a pioneer in urban customized insurance, reported 17.91 million enrollees in 2024, with RMB 976 million in payouts. Guangzhou’s "Sui Xin Bao" covers 120 non-reimbursable innovative drugs and enables one-stop settlement with basic医保. Shenzhen has already included all 19 listed drugs in its 2025 Huiminbao, with a case of a 5-year-old cancer patient receiving RMB 730,000 in drug coverage. Shantou raised reimbursement rates for listed drugs by 10 percentage points.

Experts suggest a "local pilot-first, then nationwide rollout" approach. Shanghai’s upcoming "New Group Insurance," covering 80+ high-value drugs, is projected to generate RMB 500 million–1 billion in annual payouts based on current惠民保 trends.

**Payment Revolution: Can Commercial Insurance Cover Half of China’s Trillion-Yuan Innovative Drug Market?** The list’s broader significance lies in reshaping China’s drug payment structure, which has long relied on basic医保 and out-of-pocket spending. A 2025 white paper by China Re Life, MedTrust, and BCG estimates that commercial health insurance accounted for just 7.7% (RMB 12.4 billion) of China’s RMB 162 billion innovative drug market in 2024.

The report projects that by 2035, China’s pharmaceutical market could exceed RMB 3.4 trillion, with innovative drugs reaching RMB 1 trillion. If commercial insurance follows mature markets like the U.S. and Japan, it would need to cover 44% (RMB 440 billion) of innovative drug costs—a 36-fold increase from current levels.

However, challenges remain. Commercial health insurance growth slowed to 2.3% YoY in 2025 (RMB 894.3 billion in premiums), lagging behind the broader insurance sector. Experts caution that full implementation requires strengthened risk pricing, real-world data, and policy refinement, suggesting a gradual transition from policy launch to standardized application.

As mechanisms mature, the Innovation Drug List’s role in improving drug accessibility will become clearer, balancing institutional direction with market realities.